Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
EAHAD 2026: Nine-Year Outcomes of Gene Therapy
February 2026
Nine-year data show sustained safety and reduced bleeding after gene therapy in haemophilia B, although enrichment for full viral capsids did not deliver clear clinical advantages.
Read more
5
Mins
19 Apr 2021
Rifampicin-Induced Thrombocytopenia
Thrombocytopenia is generally defined as a platelet count below the lower normal limit, <150×109/L, although many suggest that a cut-off value…
10
Mins
13 Apr 2021
Time for TIM-3: Beyond Immune Checkpoint Inhibition
TIM-3 was first discovered in Prof Kuchroo’s laboratory in 2002. This lecture reviewed the history of the discovery of TIM-3, including…
10
Mins
5 Apr 2021
Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape
As the second most common haematological malignancy, multiple myeloma (MM), a plasma cell disorder, continues to affect a significant portion of patients with increasing incidence over the past 25 years…
23 Mar 2021
Can Machine Learning Accurately Identify Malignant Blood Disorders?
YELODYSPLASTIC syndrome (MDS) is a disorder that disrupts the maturation and differentiation of haematopoietic stem cells in the bone marrow.
8
Mins
23 Mar 2021
Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most frequent non-Hodgkin lymphoma (NHL) in adults, accounting for 30–40%…
19 Mar 2021
Advanced CAR T-Cell Therapy for Multiple Myeloma
PROMISING results of a newly advanced chimeric antigen receptor (CAR) T-cell therapy showed that more than triple the period remission for multiple myeloma.
3 Mar 2021
Webinar: COVID-19 Challenges to Cancer and CAR-T Patients
This webinar has been funded by Novartis and focusses on the challenges posed by COVID-19 to cancer and CAR-T patients. Dr. Jonathan Sackier (UK) chairs…
3
Mins
9 Feb 2021
Therapeutic Plasma Exchange in Severe COVID-19 Infections
Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is a positive-sense, single-stranded RNA virus that belongs to the coronavirus family, and it is the seventh in that family known to infect humans…
Loading posts...
« Previous
1
…
65
66
67
68
69
…
100
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View